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Summary 23 
Steroid receptor drugs have been available for more than half a century, but details 24 
of the ligand binding mechanism has remained elusive. We solved X-ray structures of 25 
the glucocorticoid and mineralocorticoid receptors to identify a conserved plasticity at 26 
helix 6-7 region that extend the ligand binding pocket towards the receptor surface. 27 
Since none of the endogenous ligands exploit this region, we hypothesized that it 28 
constitutes an integral part of the binding event. Extensive all atom unbiased ligand 29 
exit and entrance simulations corroborate a ligand binding pathway that gives the 30 
observed structural plasticity a key functional role. Kinetic measurements reveal that 31 
the receptor residence time correlate with structural rearrangements observed in both 32 
structures and simulations. Ultimately, our findings reveal why nature has conserved 33 
the capacity to open up this region and highlight how differences in the details of the 34 
ligand entry process result in differential evolutionary constraints across the steroid 35 
receptors.   36 
 37 
Introduction 38 
Biological functions originate from, and are maintained by, a combination of genomic 39 
drift and selection. The traditional method to derive evolutionary relationships is to 40 
compare primary sequences, tertiary structures and protein function. However, while 41 
changes in the amino acid sequence and placement of key residues provide useful 42 
insights into lineage, this only provides the basic framework for mechanistic detail. A 43 
more complete functional understanding requires protein plasticity to be considered. 44 
Moreover, comparing protein flexibility of related systems adds an important 45 
dimension when exploring evolutionary trajectories (Bhabha et al., 2013). 46 
 47 
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The steroid receptor family consists of five closely related receptors: the 48 
mineralocorticoid receptor (MR), the glucocorticoid receptor (GR), the androgen 49 
receptor (AR), the progesterone receptor (PR) and the estrogen receptors (ERα and 50 
ERβ) (Figure. 1A). They all bind cholesterol derivatives and play a critical role in 51 
fundamental biological processes, ranging from pregnancy, early development, to the 52 
stress response and electrolyte homeostasis (Evans et al., 1988 and Mangelsdorf et 53 
al., 1995). Continual pharmaceutical efforts have resulted in several efficacious drugs 54 
across the family (Cole et al., 2006, Gravez et al., 2013, Shelle et al., 2008, Sitruk-55 
Ware et al., 2010 and Alexander et al., 2013). However, target class-related side-56 
effects limit the prescription of these drugs for many indications and the scope for 57 
further improvement is considered to be high (Bertocchio et al., 2011). The receptors 58 
share a common architecture with three separate domains: the N-terminal domain 59 
(NTD), the DNA binding domain (DBD) and the ligand binding domain (LBD). Besides 60 
recognizing the ligand pharmacophore, the LBD also contains the activation function-61 
2 (AF-2), which is important for transmitting ligand binding information and partially 62 
driving the co-regulator interaction fingerprint (Gronemeyer et al., 2004). In the 63 
resting state, the receptors are associated with chaperone proteins in the cytoplasm. 64 
Ligand activation leads to a partial release of chaperone proteins, followed almost 65 
always by nuclear translocation. In the nucleus, the receptors dimerize and form 66 
ligand and context specific protein complexes, resulting in activation and/or 67 
repression of gene transcription. 68 
 69 
All steroid receptor LBD structures exhibit the typical 3-layered alpha helical fold that 70 
fully encloses the various compounds in the ligand binding pocket (Bledsoe et al., 71 
2002, Williams et al., 1998, Fagart et al., 2005 and Matias et al., 2000), Figure 1B. 72 
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When overlaying the steroid receptors, the largest structural difference in proximity to 73 
the ligand is located in the region where helices 3, 7 and 11 meet (Li et al., 2005). 74 
Figure 1C shows a detailed comparison of GR to its paralog MR. An outward tilt of 75 
the helix 6–7 (H6-H7) interface in GR results in an expanded ligand binding pocket, 76 
and the most potent GR ligands contain large substituents extending in this direction 77 
(17α). Despite the smaller pocket in MR, several ligands with bulky 17α substituents 78 
on the steroidal D-ring, such as desisobutyrylciclesonide (dibC, the active metabolite 79 
of the pro-drug ciclesonide), are more potent in the MR binding assay than the 80 
endogenous agonist aldosterone.  81 
 82 
Plasticity in the H6-H7 region has been reported for ERα, AR and PR (Andrieu et al., 83 
2015, Nettles et al., 2007 and Kohn et al., 2012) and appears to be a conserved 84 
feature across the nuclear receptor superfamily (Soisson et al., 2008 and Hughes et 85 
al., 2012). To build a detailed understanding for how the differences in receptor 86 
design influence the H6-H7 rearrangments, we determined the X-ray structures of 87 
both MR and GR in complex with dexamethasone and dibC (Figure 1D). The 88 
structures revealed that when binding a ligand with a large 17α substituent, MR is 89 
fully capable of adopting an open structural conformation and that the nature of these 90 
rearrangements are clearly distinct from analogous changes in GR. Why has nature 91 
preserved the capacity to open up this region across the steroid receptor family, even 92 
though it is not exploited by the endogenous ligands? Our hypothesis is that the 93 
observed plasticity is an integral part of the ligand entry mechanism.  94 
 95 
To test this hypothesis we performed comprehensive all atom unbiased simulations. 96 
In these studies, we could link the observed plasticity in the H6-H7 region to the 97 
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ligand binding mechanism. While the simulations clearly identified a common binding 98 
trajectory for the two receptors, they also highlighted detailed differences in the entry 99 
and exit processes. By employing Surface Plasmon Resonance (SPR) and Single 100 
Molecule Microscopy (SMM), we could show that these differences correlate with 101 
distinct ligand-receptor residence times. Finally, we perform a bioinformatic analyses 102 
where we confirm that GR has relaxed evolutionary constraints on the H6-H7 amino 103 
acid sequence relative all other steroid receptors. The link to the ligand binding utility 104 
provides a functional understanding for these observations. 105 
 106 
Results 107 
 108 
A conserved plasticity 109 
Dexamethasone was originally developed as a GR specific agonist (Alexander et al., 110 
2013) and was used to determine the first GR LBD structre (Bledsoe et al., 2002). 111 
However, dexamethasone was later shown to also be a potent MR ligand in a 112 
functional reporter gene assay (Rupprecht et al., 1993). The X-ray structure of MR in 113 
complex with dexamethasone (MR:Dexa, Figure 2A) is similar to the corresponding 114 
GR:Dexa structure (normalized root mean square deviation (RMSD) of 0.37 Å for 100 115 
Cα atoms). However, examining the region where helices 3, 7 and 11 meet, confirms 116 
that the 17α sub-pocket is considerably smaller in the MR structure compared with 117 
the GR structure (Figure 1C). This is reflected in the total volume of the MR:Dexa 118 
ligand binding pocket, which is approximately 543 Å3 compared with 572 Å3 in the 119 
GR:Dexa structure (Figure S1). 120 
It has been proposed that structural differences in the loop between helices 6 and 7 121 
are primarily due to replacement of Ser843MR by Pro637GR, which alters the 122 
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geometrical constraints of this region and allows GR to adopt a more open 123 
conformation (Li et al., 2005). However, despite the limited size of the MR sub-124 
pocket, dibC has higher affinity than aldosterone in the scintillation proximity assay 125 
(SPA) using tritiated aldosterone and MR LBD fusion protein (Ki for dibC is 0.18 nM 126 
compared to 1.0 nM for aldosterone, Figure S2). To study the structural flexibility 127 
associated with large 17α substituents, we determined the complex structures of 128 
MR:dibC and GR:dibC. 129 
The structure of MR:dibC superimposes well on the MR:Dexa structure (normalized 130 
RMSD of 0.28 Å for 100 Cα atoms). dibC is placed in a nearly identical position as 131 
dexamethasone in the binding pocket, with all polar interactions conserved (Figure 132 
2B). In addition, the AF-2 surface remains virtually unchanged, with key interactions 133 
to the NCOA1 peptide intact. However, while these two receptor conformations are 134 
closely related, dibC induces a large rearrangement of the H6-H7 loop region, 135 
essentially extending the ligand binding pocket towards the receptor surface (Figure 136 
3A). Specifically, side chains of Ser843MR, Met845MR and Cys849MR in the MR:Dexa 137 
complex occupy the same volume as the cyclohexyl motif of dibC, forcing the 138 
receptor to adopt a new conformation (Figure 3B). This leads to a repositioning of 139 
helix 6 and an extension of helix 7. While Ser843MR was previously buried within the 140 
protein and engaged in a hydrogen bond to the backbone nitrogen of Met845MR, it is 141 
now exposed to the solvent, forming the new start of helix 7 (Figure 3A). Recent data 142 
suggests that phosphorylation of this residue affects both ligand binding and receptor 143 
translocation into the nucleus (Shibata et al., 2013). The structural changes observed 144 
here explain how the receptor may use the local plasticity to make Ser843MR 145 
available for modification.  146 
 147 
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The size of the 17α pocket in the MR:dibC complex increases significantly (total 148 
ligand binding pocket volume 714 Å3, Figure S1) and the superposition on the 149 
GR:Dexa structure shows that this region now adopts a more closely related 150 
structural state (Figure 3C). Finally, while GR in complex with dibC (Figure 3D) 151 
expands the 17α pocket (total ligand binding pocket volume 661 Å3, Figure S1) 152 
relative to the GR:Dexa structure, it does not alter any of the secondary structural 153 
elements. Instead, the H6-H7 region appears to be shifted in a rigid way in response 154 
to cyclohexyl of dibC. While plasticity in the H6-H7 region seems to be conserved 155 
across these two receptors, the details of the ligand driven rearrangements are 156 
different. 157 
To quantify the flexibility in the H6-H7 region across the steroid receptor family, we 158 
performed principal component analysis (PCA) for all X-ray structures from the 159 
protein data bank (PDB) for each receptor. This allows visualization of the variance 160 
between structures as a set of normal modes. While the description of this variance 161 
will be highly dependent on what regions of the binding pocket are exploited by the 162 
various ligands, the mode describing H6-H7 motion is one of the strong features 163 
(Figure S3). However, for MR the H6-H7 motion is only prominent if we include the 164 
MR:dibC structure from this work, emphasizing that the MR:dibC structure describes 165 
a novel structural conformation.  166 
 167 
Modeling non biased entry and exit pathways 168 
Spontaneous ligand binding events have been investigated using molecular 169 
dynamics in both exposed (Buch et al., 2011), and partially exposed binding sites 170 
(Dror et al., 2011). However, nuclear receptors have fully occluded binding pockets 171 
that likely require significant rearrangements for ligand entry. Therefore we decided 172 
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to use PELE (Borrelli et al., 2005), which is an alternative approach that use Monte 173 
Carlo algorithms with structural prediction for efficient sampling of the protein-ligand 174 
energy landscape. For ligand escape simulations the MR and GR X-ray complex 175 
structures were used as the starting position. For ligand binding studies, the ligand 176 
was randomly placed in the bulk solvent and allowed to freely migrate. All simulations 177 
were completed in the presence and absence of a co-factor peptide at the AF-2 site 178 
(NCOA1 residues 1430-1441 for MR and NCOA2 residues 741-753 for GR). In 179 
addition, both the wild-type protein sequences and the specific mutants present in the 180 
X-ray structures were used. 181 
 182 
Ligand dissociation 183 
For all permutations of both MR and GR, we performed three separate exit 184 
simulations, observing only one exit trajectory perforating the surface where helices 185 
3, 7 and 11 meet. Figure 4A illustrates the MR:Dexa exit pathway simulation with the 186 
array of dexamethasone positions superimposed on the initial MR structure. Notably, 187 
ligand motion is coupled with significant rearrangement of the protein backbone 188 
along the migration pathway. In particular, the loop connecting helices 6 and 7 is 189 
shifted outwards to accommodate ligand release (Figure 4B). Interestingly, the 190 
simulated protein movements mimic the differences between the MR:Dexa and 191 
MR:dibC structures shown in light and dark blue, respectively. Root mean square 192 
fluctuations (RMSF) along the exit trajectory (Figure 4C) clearly show that the 193 
movements of the H6-H7 region are considerable larger than for the rest of the 194 
protein. 195 
 196 
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Figure 5 shows the corresponding simulation for GR:Dexa (equivalent simulations for 197 
MR:dibC and GR:dibC resulted in the same exit trajectory). Based on the complete 198 
set of ligand dissociation simulations it is apparent that both MR and GR have the 199 
same ligand unbinding pathway. In addition, while ligand exit is associated with 200 
similar protein motions, the fluctuations in the H6-H7 region are significantly larger for 201 
MR than for GR (Figure 5c). This is in agreement with the idea that GR would require 202 
smaller rearrangements, because the receptor is more open to begin with. 203 
 204 
Ligand association 205 
To investigate ligand entry we randomly placed dexamethasone in the bulk solvent 206 
and released it to freely probe the protein surface. For each receptor we performed 207 
five runs with 64 independent trajectories over 48 hours. Each run yielded 1-2 208 
trajectories where the ligand entered the binding pocket. In all runs the ligand is free 209 
to move without any predefined search direction.  210 
Figure 6A shows the evolution of the ligand heavy atom RMSD to the crystallographic 211 
complex for one of the MR:Dexa runs. It is clear that most of the trajectories explore 212 
the receptor surface with some excursions into the bulk solvent. However, the blue 213 
and red trajectories enter the ligand binding pocket at steps ~50 and ~210, 214 
respectively. While the entry along the blue trajectory is relatively fast, the red 215 
demonstrates the unbiased nature of the simulation, probing a large portion of the 216 
receptor surface before finding the entrance pathway. Figure 6B shows 217 
representative ligand centers of mass along these trajectories superimposed on the 218 
initial protein structure with the entry to the binding pocket denoted by a surface 219 
representation. The corresponding ligand entry simulation for GR is shown in Figure 220 
S4. In keeping with the ligand escape simulations for all runs in both systems, 221 
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trajectories entering the ligand binding pocket pierce the protein surface at the H3-222 
H7-H11 junction. The MR:Dexa binding event is demonstrated in greater detail in the 223 
Supplementary movie.  224 
While the mutants used in the X-ray structures did not influence the simulations 225 
significantly, removal of co-factor peptide at the AF-2 resulted in larger fluctuations in 226 
both the helix 12 and the H3-H7-H11 junction along the exit and entrance 227 
trajectories. However, the ligand entry pathway remained unchanged. The presence 228 
of co-regulator peptide has been shown to affect the ligand binding kinetics (Pfaff et 229 
al., 2010).  230 
 231 
Active site ligand refinement and binding free energy 232 
Once the entrance path to the MR binding pocket had been located, we refined the 233 
free search with local enhanced sampling to obtain a precise pose for the best 234 
binder. This procedure does not add any bias in the ligand search direction, but it 235 
limits the sampling to the region around the entrance point (typically 10-15 Å). Figure 236 
7A shows the interaction energy profile plotted against the ligand heavy atom RMSD 237 
to the crystallographic complex for the MR:Dexa refining process (400 trajectories). 238 
The lowest binding energies are derived from poses located within 0.75 Å RMSD of 239 
the X-ray ligand conformation. The sampling places dexamethasone in the accurate 240 
orientation with the A-ring 3-keto moiety pointing toward the Arg817MR-Gln776MR pair 241 
from helices 5 and 3, and the D-ring hydroxyacetyl approaching the Asn770MR on the 242 
N-terminal half of helix3 (Figure 7B). Studying the protein-ligand interaction energy 243 
plot in more detail (Figure 7A), it is interesting to note that the surface exploration 244 
exhibit a local minima near RMSD of 12 Å. In the crystal structure of GR:Dexa and 245 
GR:dibC, this site is occupied by a steroid-like CHAPS molecule that is part of the 246 
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protein formulation (Figure S5). In addition, for MR a non-steroidal antagonist has 247 
been observed at this position (Hasui et al., 2011). As such, the region may 248 
correspond to a peripheral binding site at the H3-H7-H11 junction and the energy 249 
barrier located at the 11-12 Å segment in Figure 7A reflect the energy cost 250 
associated with the surface crossing event through the entry channel.  251 
The fast performance of PELE, together with the local restriction in the refinement 252 
exploration, facilitates running hundreds of trajectories. Based upon Markov State 253 
Model (MSM) analysis (Takahashi et al., 2014), we used this data to calculate the 254 
binding free energies for MR:Dexa and MR:dibC. While absolute values might be 255 
slightly shifted due to the absence of an exhaustive surface/bulk exploration, relative 256 
values should be in reasonable agreement, because both ligands share entry point 257 
and binding site. Figure 7C shows a 2D projection of the potential mean field (PMF) 258 
obtained for MR:Dexa along the 400 refinement trajectories. The red area 259 
corresponds to the bulk exploration whereas the global minimum, shown in blue, 260 
corresponds to ligand positions matching the experimental structure (Figures 7A and  261 
B). Integration of the PMF volume at the active site, where we observe a smooth 262 
function (as opposed to the bulk solvent or entrance pathway) converges to a binding 263 
free energy of -7.5 kcal/mol for dexamethasone and -9.3 kcal/mol for dibC. The 264 
difference in binding free energy of 1.8 kcal/mol is in quantitative agreement with the 265 
experimental difference of 2.09 kcal/mol (derived from the Ki values of 6.3 nM for 266 
dexamethasone and 0.18 nM for dibC). 267 
 268 
Residence time measurements 269 
The ligand entry and exit mechanism establishes a functional role for helices 6 and 7 270 
as a gatekeeper. In addition, the simulations revealed that the structural 271 
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rearrangements required for ligand entry and exit are significantly different for GR 272 
and MR. As a consequence, the ligand binding kinetics should differ for the two 273 
receptors. Using both Surface Plasmon Resonance (SPR) and Single Molecule 274 
Microscopy (SMM) (Gunnarsson et al., 2015), we measured the residence time of 275 
both dexamethasone and dibC by monitoring the time-resolved change in receptor 276 
binding to a surface-immobilized co-regulator peptide upon addition of >10-fold 277 
concentration excess of a reference compound (Figure S6). The data from all 278 
experiments is summarized in Table 2. In all instances, koff is larger for GR than for 279 
MR, hence the residence time is longer in MR. This is in agreement with the 280 
observations that MR requires a larger rearrangement of the H6-H7 region compared 281 
to GR (Figure 4 and Figure 5). In addition, dexamethasone has a larger koff than 282 
dibC, reflecting the fact that dibC is a bulkier ligand. Finally, while the different 283 
measurement methods result in the same pattern for both GR and MR and 284 
dexamethasone and dibC, providing confidence to the analysis, the systematically 285 
larger off-rates using SMM likely reflect the temperature difference at which the 286 
experiments were conducted (20 °C for SMM and 10 °C for SPR). 287 
 288 
Differential selection pressure 289 
Studies on the evolution of GR from the ancestral corticoid receptor revealed that GR 290 
has accumulated a number of mutations on and in the proximity of helix 7 that 291 
prevents reversal of evolution (Bridgham et al., 2009). As our findings suggest that 292 
there is an intimate link to the ligand binding function we decided to investigate the 293 
evolutionary consequences across the whole steroid receptor family. To explore this, 294 
sequence clusters for each receptor were downloaded from OrthoDB (Waterhouse et 295 
al., 2013). The sequences for each receptor were aligned using ClustalX version 2.0 296 
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(Larkin et al., 2007) and the pairwise species overlap with GR was selected for each 297 
receptor. Each residue position was then assigned a variability score based on the 298 
number of different amino acids at that position across the various species. All 299 
receptor sequences were overlaid on the GR sequence using X-ray structures to 300 
define the equivalent positions. Finally, we plotted the variability score against the 301 
amino acid sequence for all receptor pairs (Figure 8). The data confirms that 302 
important structural elements of the receptors are relatively conserved. For example, 303 
the variability score for the AF-2 surface (the N-terminal end of H12, H4 and the C-304 
terminal end of H3), which is directly involved in the protein-protein interaction 305 
transmitting the ligand activation signal, is consistently low for all receptors. However, 306 
H6-H7 exhibits a greater variability score in GR relative to all other receptors. 307 
Interestingly, GR also has a segment of higher variability near the C-terminal end of 308 
H11. This region sits directly across from the N-terminal end of H7 (Figure 1C) and it 309 
is conceivable that amino acid sequences of these regions may well co-vary with 310 
each other. Figure S7A shows the variability score for the individual amino acids in 311 
the H6-H7 region for the full set of GR species. It is clear that the high variability 312 
score of the region resides in discrete positions (primarily in residues 631, 632, 635, 313 
638 and 640). These residues are all located on the outside of the receptor in both 314 
the GR:Dexa and GR:dibC structures (Figure S7B). 315 
 316 
Discussion  317 
The fundamental role and mechanism of action of steroid receptors have been 318 
studied extensively, yet details of the ligand binding mechanisms have remained 319 
unclear. By comparing the structures of MR and GR in complex with dexamethasone 320 
and dibC, we confirmed the intrinsic capacity to open up the H6-H7 region. While the 321 
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GR:Dexa structure adopts an open conformation compared with the MR:Dexa 322 
complex, the MR:dibC structure is able to extend the ligand binding pocket 323 
significantly and adopt a structural state akin to the GR:Dexa arrangement. Studies of 324 
ancestral corticoid receptor (AncCR), the common predecessor of MR and GR, 325 
revealed that the Ser106AncCR (corresponding to Ser843MR) to Pro637GR switch was a 326 
permissive mutation that facilitated a subsequent Leu111AncCR (corresponding to 327 
Leu848MR) to Gln642GR mutation (Bridgham et al., 2006). This is an example of 328 
conformational epistasis and has played an important role for the evolution of the GR 329 
hormone selectivity (Ortlund et al., 2007). We show that GR and MR demonstrate a 330 
similar capacity to form an open conformation, and it is likely that the AncCR also 331 
exhibited the same flexibility. Hence, as GR evolved from AncCR, the Ser106AncCR to 332 
Pro637GR mutation would primarily serve to select a subset of pre-existing structural 333 
states, rather than creating a completely new arrangement. The importance of 334 
conformational selection over induced fit has provided mechanistic insights for 335 
several biological systems (Changeux et al., 2013), it is plausible that evolution 336 
through mutation often operates in an analogous way.   337 
 338 
Extensive ligand binding simulations revealed that the entry and exit trajectories all 339 
pass through the H3-H7-H11 junction. As the ligand cross the receptor surface, the 340 
outward bending motion of the H6-H7 region is qualitatively similar to the observed 341 
perturbations caused by the large 17-α cyclohexyl substituent in the dibC complex 342 
structures, linking the observed H6-H7 plasticity to the ligand binding mechanism. 343 
Interestingly, H7 has also been shown to be important for dimerisation of several 344 
nuclear receptors (Osz et al., 2012). This suggests that the two functions could be 345 
linked for these receptors, but the strength of that relationship remains to be 346 
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determined. The results from the ligand binding simulations indicate that large-347 
amplitude protein motions of helix 12, as suggested by apo and holo crystallographic 348 
nuclear hormone receptors (Moras et al., 1998, Yen et al., 2001 and Brzozowski et 349 
al., 1997), are not required for ligand entry. Instead, the conformation of the LBD is 350 
likely to resemble the ligand bound agonistic conformations of the receptors during 351 
the ligand entry step (Capelli et al., 2013 and Batista et al., 2013). We show that 352 
small scale vibrations combined with a structural rearrangement of H6-H7 region are 353 
enough to identify an energetically favorable pathway to allow the ligands to diffuse 354 
into the binding pocket. In contrast to other modeling studies using biased protocols, 355 
we do not observe multiple ligand entry or exit pathways (Capelli et al., 2013, Sonoda 356 
et al., 2008 and Aci-Sèche et al., 2011). Finally, careful analysis of the binding 357 
energies along the entry trajectory revealed a potential peripheral binding site. While 358 
it requires further characterization, the function of such a site on the surface of the 359 
receptor could serve to capture the ligands and increase the chances for productive 360 
binding events. 361 
 362 
It is firmly established that steroid receptors depend on a number of chaperone and 363 
co-chaperone proteins for correct folding capable of high-affinity hormone binding 364 
(Grad et al., 2007). Although the ligand entry function is likely to have evolved before 365 
the synergies with chaperone proteins, these proteins will nevertheless limit the 366 
access to the receptors and thereby form boundary conditions for any ligand entry 367 
hypothesis. Mutation and peptide competition studies suggest that Hsp90 is 368 
interacting at the AF-2 surface (Ricketson et al., 2007 and Fang et al., 2006). In 369 
addition, co-chaperones have been mapped to interact with regions surrounding the 370 
C-terminal end of H1 and the N-terminal end of H3 (Caamaño et al., 1998), and with 371 
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the loop that connects them (Cluning et al., 2013). Neither of these areas overlap 372 
with the entry site proposed here. However, previous studies have shown that the 373 
chaperone complex promote the ligand binding process (Grad et al., 2007). 374 
Interestingly, the simulations where we removed the co-regulator peptides resulted in 375 
greater fluctuations in both the H3-H7-H11 junction and H12. These results suggest 376 
that the presence of chaperone proteins at remote sites can allosterically influence 377 
the ligand entry process proposed here.     378 
 379 
While the dibC complex structures show that both corticoid receptors can adopt an 380 
open conformation, they also highlight that the plasticity in the H6-H7 region is 381 
different. For MR, the challenge from a large 17α substituent results in a complete 382 
rearrangement of the H6-H7 structure. In contrast, GR responds with a rigid shift of 383 
the region. A closer inspection of the simulations revealed ensuing differences as MR 384 
require larger rearrangements in the gatekeeper residues for productive ligand 385 
binding and unbinding. This is in agreement with the kinetic measurements revealing 386 
that both dexamethasone and dibC exhibit longer receptor residence times in MR 387 
than GR. However, these observations do not necessarily result in differences in 388 
ligand affinity per se as both ligand entry and exit will be governed by the same 389 
plasticity, potentially affecting on and off rates equally. Nevertheless, it is important to 390 
note that ligand binding and unbinding are asymmetric events. While ligand binding 391 
occurs with the receptor in the chaperone complex in the cytoplasm, unbinding will 392 
likely occur in the different protein complex. As such, it is tempting to speculate that 393 
the relative stabilization of the open versus the closed conformation may differ for the 394 
two states. This could increase the apparent ligand affinity and potentially add 395 
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another layer of differentiation. To resolve this, detailed structural information on the 396 
relevant protein complexes would be required.  397 
 398 
The distinct receptor blueprints also appear to have evolutionary consequences. By 399 
comparing the amino acid sequence for different species across all steroid receptors, 400 
we found that GR exhibits a higher mutational frequency in the H6-H7 region. We 401 
propose that as GR evolved a cortisol selectivity profile, the change in the dynamic 402 
profile of the H6-H7 region, through the Ser106AncCR to Pro637GR mutation, altered 403 
the boundary conditions for the ligand entry mechanism. While for MR, residues need 404 
to be compatible with two distinct structural states during ligand entry, for GR, the 405 
equivalent residues will be exposed to the solvent throughout the process. As a result 406 
the selection pressure was relaxed for specific positions in this region for GR, which 407 
explains why subsequent mutations could build.  408 
 409 
The tremendous growth in the number of available X-ray structures from increasingly 410 
more advanced protein classes and complexes provides a plethora of snapshots of 411 
molecular mechanism in action. However, to bridge the gap to detailed mechanistic 412 
insights and to establish evolutionary relationships, orthogonal data from biochemical 413 
experiments and in silico modeling are required. By combining information from 414 
several X-ray structures, extensive simulations, kinetic measurements and 415 
bioinformatic analyses, we have uncovered the ligand binding mechanism into the 416 
occluded binding pocket of steroid hormone receptors. Ligand binding to the steroid 417 
receptors marks the first step in a chain of events that in the end triggers both broad 418 
genomic and non-genomic mechanisms. Understanding the details of ligand 419 
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association and dissociation may facilitate the rational design of molecules that 420 
exploit the plasticity of the entry and exit processes to a greater extent. This could 421 
yield ligands with different modes of action, such as antagonists that block nuclear 422 
translocation or agonists with extended receptor occupancy and a prolonged 423 
pharmacological response. 424 
 425 
Experimental Procedures 426 
 427 
Protein expression, purification, crystallization, structure determination and 428 
analyses 429 
The detailed protocols are described in the supplementary methods section. For 430 
structure, the following protein constructs were used: GR:Dexa, GR-LBD (amino 431 
acids 500-777) N517D, F602S, C638D; GR:dibC, GR-LBD (amino acids 500-777) 432 
N517D, V571M F602S, C638D; MR:Dexa, MR-LBD (amino acids 735-984) C808S, 433 
C910S;  MR:dibC, MR-LBD (amino acids 735-984) C808S, S810L C910S. For the 434 
kinetic measurements, the following constructs were used: GR, GR-LBD (NR3C1; 435 
amino acids 529-777); MR, MR-LBD (amino acids 712-984) C808S. 436 
 437 
Mineralocorticoid receptor ligand competition binding assay 438 
 439 
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A Scintillation proximity (SPA) based radioligand binding assay was used to measure 440 
the ligand displacement of aldosterone to human MR-LDB. Detailed protocol is 441 
presented in the supplementary experimental procedueres. 442 
 443 
PELE simulations  444 
Systems setup 445 
Initial coordinates for GR and MR were obtained from the crystals presented here. 446 
Three different receptor models were prepared: 1) the crystallographic structures, 2) 447 
the wild type receptors generated by reverting the crystallographic mutations with the 448 
Schrödinger package (Schrödinger 2013) , and 3) the wild type receptors in absence 449 
of the peptide cofactor. All structures were preprocessed with the protein preparation 450 
wizard (Madhavi Sastry et al., 2013) available in the Schrödinger package adding 451 
hydrogen atoms and optimizing the hydrogen bond network, followed by a final visual 452 
inspection.  453 
 454 
PELE sampling 455 
PELE combines a Monte Carlo approach with protein structure prediction methods 456 
allowing exploration of long-timescale atomic biophysical processes (Borrelli et al., 457 
2005; Cossins et al., 2012). Three main steps define the algorithm: 1) protein 458 
backbone and ligand perturbation, 2) specific side-chain sampling and 3) global 459 
minimization (for more details see, for example, Kotev et al., 2015). The program 460 
uses an OPLS (Optimized Potentials for Liquid Simulations) all-atom force field with 461 
an implicit surface-generalized Born (SGB) continuum solvent model. 462 
 463 
Ligand exit simulations  464 
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From the crystallographic prepared models, the exit protocol included random 465 
ligand’s translations of 0.8 Å and rotation of 0.2 radians. The backbone perturbation 466 
included the lowest 6 ANM modes with maximum displacements of each alpha 467 
carbon up to 1 Å. A spawning criteria of 4 Å was used: any ligand whose center of 468 
mass is 4 Å behind the structure with the center of mass farthest coordinates (with 469 
respect to the initial position), in any direction, will abandon its position and continue 470 
the execution with the coordinates from the leading (farthest) one. Thus, all 471 
processors search collectively, with no bias in direction, for an effective escape path. 472 
Simulations were finished after the ligand’s solvent accessible area (SASA) was 473 
larger than 0.5, with typical simulations times of 10-20 CPU hours. 474 
 475 
Ligand entrance simulations  476 
Starting from 20 conformations where the ligand is randomly distributed over the 477 
protein surface., free search simulations were performed with runs of 64 independent 478 
simulations (no spawning criteria was used) for 48 CPU hours. Ligand perturbation 479 
included equally probable translations of 3.0 Å / 1.0 Å and rotation of 0.25/0.05 480 
radians.. Ligands displacement direction was randomly updated every 6 steps, thus 481 
ensuring that trajectories explore the entire surface. Furthermore, keeping the 482 
perturbation direction for 6 steps is necessary to observe entrance events in difficult 483 
cases.  484 
 485 
Residence time determination 486 
Residence time measurements of GR/MR:dexamethasone and dibC was determined 487 
using single molecule microscopy (SMM) and SPR (Biacore). In brief, GR/MR was 488 
pre-equilibrated with dexamethasone/dibC. Directly after addition of 489 
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budesonide/aldosterone, the rate of receptor binding to the surface-immobilized 490 
cofactor peptide, caused by the ligand-induced change in affinity, was monitored 491 
continuously over ~15 minutes with SMM or by consecutive injection cycles (typically 492 
6) in SPR. See supporting information for details on surface preparation and 493 
experimental procedure. The dissociation rate is was determined by exponential fits 494 
to the change in binding rate as a function of time. 495 
 496 
Sequence homology analysis 497 
Sequence clusters for each receptor were downloaded from the OrthoDB database 498 
(Waterhouse et al., 2013) by searching for the human ENS gene ID and selecting the 499 
vertebrate subset. For each receptor, sequences with a length two standard 500 
deviations below average length or that contained more than 100 ‘X’ (unknown amino 501 
acids) were removed. The sequences for each receptor were aligned using ClustalX 502 
version 2.0 (Larkin et al., 2007), then further filtered to only keep sequences with an 503 
intact H6-H7 region (max 1 indel or ‘X’ and >= 50% identity to the human H6-H7 504 
region; sequences with large indels in H6-H7 were removed followed by realignment 505 
and refiltering to correct for alignment errors around indels). The filtered sets were 506 
scored using custom perl scripts; for each position in the alignment, a variability score 507 
was calculated by counting the number of different types of amino acids (i.e. if a 508 
position contained 5F, 3Y and 9L, then the score is 3). In order to remove bias 509 
stemming from the inclusion of sequences from different species across the various 510 
receptors, subsets were generated where the same species were included for pairs 511 
of GR with either of [MR, PR, AR, ERα and ERβ]. The paired subsets were realigned 512 
for each receptor and the resulting alignments were analyzed and scored as 513 
previously described. Finally, the scores were normalized (variability score - average 514 
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variability score for LBD) and smoothed using a sliding window of 5 amino acids and 515 
plotted against the GR protein sequence. 516 
 517 
Phylogenetic analysis of the human LBD region 518 
Human sequences for the studied nuclear receptors (AR, ERα, ERβ, GR, MR and 519 
PR) were extracted from the aforementioned dataset. Sequences were trimmed so 520 
that only the LBD region remained, aligned using ClustalX and then manually edited 521 
based on the structure (minor adjustments). The tree was calculated using ClustalX 522 
(bootstrap 1,000 iterations) and visualized using NJplot version 2.3 (Perrière et al., 523 
1996)  524 
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 764 
Figure 1.  765 
Evolutionary relationship of the steroid receptors with structural comparison of 766 
GR and MR LBD 767 
(A) Evolutionary relationship of the steroid hormone receptors (ERα, ERβ, MR, GR, 768 
PR and AR; decimal numbers = distance; integers = bootstrap value).  769 
(B) GR (yellow) in complex with dexamethasone (magenta) overlaid on MR 770 
(lightblue) in complex with dexamethasone (magenta). The AF-2 surface is located 771 
where helices 3,4 and 12 meet.  772 
(C) Details near the region where helices 3, 7 and 11 meet.  773 
(D) The chemical structures of dexamethasone and dibC. The steroidal A, B, C and D 774 
rings and positions 3 and 17 are marked on the dexamethasone structure. 775 
 776 
Figure 2. 777 
Comparison of the complex structures of the MR:Dexa and MR:dibC 778 
(A) Stereo view of the 2mFo-dFc density map of the MR:Dexa ligand binding pocket. 779 
(B) The structure of MR (light blue) in complex with dexamethasone (magenta) 780 
superimposed on MR (dark blue) in complex with dibC (white). The steroid template 781 
overlays nearly perfectly (RMSD 0.28 Å) with all hydrophilic interactions conserved.  782 
 783 
 784 
Figure 3.  785 
Comparison of the complex structures of MR:Dexa, MR:dibC, GR:Dexa and 786 
GR:dibC 787 
35 
 
(A) MR (light blue) in complex with dexamethasone (magenta) overlaid on MR (dark 788 
blue) in complex with dibC (white).  789 
(B) The cyclohexyl motif of dibC come into direct conflict with residues from H7 790 
(MR:Dexa), enforcing a new structural state.  791 
(C) MR (dark blue) in complex with dibC (white) superimposed on GR (yellow) in 792 
complex with dexamethasone (magenta).  793 
(D) GR (yellow) in complex with dexamethasone (magenta) overlaid on GR (orange) 794 
in complex with dibC (white).  795 
 796 
 797 
Figure 4.  798 
Ligand exit pathway for the MR:Dexa complex 799 
(A) The ligand center of mass is highlighted in blue beads. The ligand atoms are 800 
shown in transparent spacefill.  801 
(B) Detail of the backbone rearrangement along the exit pathway. The MR:Dexa and 802 
MR:dibC X-ray structures are shown in light and dark blue, respectively, with 803 
dexamethasone in the binding pocket in magenta. Three protein cartoon snapshots 804 
and one pose of dexamethasone as it pass through the receptor surface from the exit 805 
simulations are shown in green.  806 
(C) Cα RMSF relative the average structure along the MR:Dexa exit pathway plotted 807 
for each residue. The dotted line denotes the average RMSF across the LBD. Helices 808 
6 and 7 are marked with green shade.  809 
 810 
 811 
 812 
 813 
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Figure 5.  814 
Ligand exit pathway for the GR:Dexa complex.  815 
(A) The ligand center of mass is highlighted in blue beads. The ligand atoms are 816 
shown in transparent spacefill. (B) Detail of the backbone rearrangement along the 817 
exit pathway. The GR:Dexa and GR:dibC X-ray structures are shown in light yellow 818 
and orange, respectively. Three snapshots from the exit simulations are shown in 819 
green and dexamethasone in the binding pocket is shown for reference in magenta. 820 
(C) Cα RMSF relative the average structure along the GR:Dexa exit pathway where 821 
helices 6 and 7 are marked with green shade.  822 
Figure 6.  823 
Unbiased simulation of dexamethasone entering the MR binding pocket 824 
(A) Each line represents the ligand heavy atom RMSD to the ligand from the 825 
crystallographic structure for a single trajectory. Two of the trajectories represented 826 
by blue and red lines enter the ligand binding pocket at step 52 and 214, 827 
respectively.  828 
(B) The ligand center of mass for the two trajectories that enter the binding pocket 829 
are shown as blue and red spheres. The region where the ligands enter the binding 830 
pocket is emphasized as a surface with two ligands from the simulations shown in full 831 
stick representation.  832 
 833 
  834 
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 835 
Figure 7.  836 
Refined ligand binding simulations and estimated binding free energy  837 
(A) The protein-ligand interaction energy plotted against the ligand heavy atom 838 
RMSD to the crystallographic structure along the 400 refinement trajectories in 839 
MR:Dexa.  840 
(B) MR (blue) in complex with dexamethasone (magenta) overlaid on the lowest 841 
interaction energy structure after the refined exploration (green).  842 
(C) X-Z 2D projection of the PMF obtained in the MSM analysis for the same 843 
process. 844 
 845 
Figure 8 846 
Evolutionary conservation of the LBD for the steroid receptors 847 
The graphs show normalized amino acid variability score for pairwise comparisons of 848 
MR (A), PR (B), AR (C), ERα (D) and ERβ (E) in blue vs GR in red plotted against 849 
the GR amino acid sequence. The variability score was average normalized and 850 
smoothed using a 5 amino acid sliding window. Helices 1-12 are annotated using 851 
vertical bars (green: H6-7; blue: H10-11; gray: all others). High variability scores 852 
indicate less conservation. 853 
 854 
 855 
Table 1. Data collection and refinement statistics.  856 
 MR: Dexa MR: dibC GR:dexa GR:dibC 
Data collectiona     
PDB ID 4uda 4udb 4udc 4udd 
Space group P212121 P41212 P3221 P3221 
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    a, b, c (Å) 73.00, 81.40, 
45.23 
75.92, 75.92, 
117.00 
84.66, 84.66, 
105.91 
87.20, 87.20, 
102.89 
    α, β, γ  (°)  90.00, 90.00, 
90.00 
90.00, 90.00, 
90.00 
90.00, 90.00, 
120.00 
90.00, 90.00, 
120.00 
Resolution (Å) 40.7-2.03 (2.17-
2.03) 
48.79-2.36 (2.55-
2.36) 
31.81-2.50 
(2.67-2.50) 
40.14-1.80 (1.85-
1.80) 
Rsym (Rmerge) 0.06(0.50) 0.13(1.30) 0.08(0.55) 0.08(1.05) 
I / σI 13.10(2.30) 15.10(1.90) 8.80(1.60) 7.40(0.70) 
Completeness (%) 83.9(83.7) 100.0(100.0) 99.6(99.5) 99.9(100.0) 
Redundancy 3.3(2.5) 12.6(11.7) 4.1(4.2) 3.5(3.6) 
Refinement     
Resolution (Å) 2.03 2.36 2.50 1.80 
No. reflections 15085 14672 15559 42339 
Rwork / Rfree 0.185/0.240 0.182/0.218 0.210/0.253 0.213/0.224 
No. atoms     
    Protein 2080 2118 2133 2184 
    Ligand/ion 34 49 64 146 
    Water 101 60 83 250 
B-factors     
    Protein 30.14 53.25 49.72 33.25 
    Ligand/ion 22.12 44.16 34.51 23.55 
    Water 36.03 56.86 46.23 46.95 
R.m.s. deviations     
    Bond lengths (Å) 0.010 0.010 0.010 0.010 
    Bond angles (°) 1.01 1.04 1.12 1.06 
Molprobity score     
    Clashscore 2 1 1 1 
    Ramachandran outliers (%) 0 0 0.4 0 
    Sidechain outliers (%) 1.7 1.7 2.5 0.8 
 aValues in parentheses are for highest-resolution shell.  857 
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Table 2. Measurement of koff  using SPR and SMM. 858 
Ligand (method) GR MR 
Dexa (SPR, 10 ºC) 0.0034 s-1 0.0011 s-1 
dibC (SPR, 10 ºC) 0.0010 s-1 <0.0001 s-1 
Dexa (SMM, 20 ºC) 0.0070 s-1 0.0025 s-1 
dibC (SMM, 20 ºC) 0.0029 s-1 0.0012 s-1 
 859 
  860 
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 861 
Figure S1, Related to Figure 3. Comparison of the volume of the ligand binding 862 
pocket in MR and GR in complex to Dexa and dibC. (A) The structure of MR (light 863 
blue) in complex with dexamethasone (magenta) overlaid on MR (dark blue) in 864 
complex with dibC (white). Ligand binding pockets are shown for MR:Dexa in brown 865 
(total volume 543 Å3) and MR:dibC in gray (total volume 714 Å3). (B) The structure of 866 
GR (pale yellow) in complex with dexamethasone (magenta) overlaid on the GR 867 
structure (orange) in complex with dibC (white). Ligand binding pockets are shown for 868 
GR:Dexa in brown (total volume 572 Å3) and GR:dibC in gray (total volume 661 Å3). 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
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 879 
Figure S2, Related to Figure 7C. MR binding competition assay in the presence of 880 
dibC (triangle), aldosterone (circle), and dexamethasone (square). The 881 
corresponding IC50 values (mean ± SD, n=3) are: 0.7 ± 0.0 nM (dibC); 4.0 ± 0.2 nM  882 
(aldosterone); 26.0 ± 4.6 nM (dexamethasone). 883 
  884 
42 
 
 885 
 886 
Figure S3, Related to Figure 3. Principal component analysis (PCA) for all X-ray 887 
structures of the steroid hormone receptors in the protein databank (PDB). The 888 
graphs show the amplitude of the top six modes from the PCA for MR (A), GR (B), 889 
PR (C), AR (D) and ER (E). The H6-H7 region which undergo the largest changes in 890 
the MR:dibC structure and the corresponding region in the other receptors are 891 
highlighted in green (MR: 837-848; GR: 631-642; PR: 786-797; AR: 772-783; and 892 
ER: 412-424). AR and MR exhibits the smallest variation in the H6-H7 region in the 893 
public domain structures. (F) The PCA of the MR public domain structures with 894 
MR:dibC added. In this analysis the mode describing the H6-H7 rearrangement 895 
becomes the dominant signal in the first mode. 896 
 897 
 898 
  899 
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900 
 Figure S4, Related to Figure 6. Unbiased simulation of dexamethasone entering 901 
GR. (A) Each line represents the ligand heavy atom RMSD to the crystallographic 902 
structure for the total 64 trajectories. One of the trajectories represented by blue line 903 
enter the ligand binding pocket at step ~310. (B) The ligand’s center of mass for the 904 
one trajectory that enter the binding pocket are shown as blue spheres. The region 905 
where the ligand enter the binding pocket is emphasized as a surface with the ligand 906 
shown in stick representation.  907 
  908 
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 909 
Figure S5, Related to Figure 3. The peripheral binding site. The structure of of GR 910 
(yellow) in complex with dexamthasone (magenta) revealed that a CHAPS molecule 911 
(white) from the protein formulation is binding in between helices 7 and 11 about 12 912 
Å away from the ligand binding pocket. 913 
    914 
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915 
  916 
Figure S6, Related to Table 2. Residence time measurements of dexamethasone 917 
(blue diamonds) and dibC (red circles) bound to GR (A, B) and MR (C, D) using 918 
SMM (A, C) and SPR (B, D). Normalized change in receptor binding rate to 919 
surface-immobilized co-regulator peptide upon addition of >10-fold concentration 920 
excess of budesonide (GR) or aldosterone (MR). The extracted binding rates are 921 
fitted with 𝑘𝑘+(𝑡𝑡) = 𝑎𝑎𝑒𝑒−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡 + 𝑐𝑐 (colored solid lines). SMM and SPR experiments were 922 
conducted 20 °C and 10 °C, respectively.  923 
 924 
 925 
 926 
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 927 
Figure S7, Related to Figure 8. Variability score and structural arrangement  of 928 
amino acids in the H6-H7 region in GR. (A) The GR variability scores plotted against 929 
the amino acid positions of the H6-H7 region. Higher scores indicate more variation 930 
at that position across the various species; a score of 1 indicate completely 931 
conservation. (B) Placement of amino acids with high variability score in the H6-H7 932 
region in the GR:Dexa (yellow) and GR:dibC (orange) structures.  933 
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Supplementary Movie, Related to Figure 4. Unbiased simulation of 934 
dexamethasone entry into MR obtained with the PELE (Protein Energy Landscape 935 
Exploration) software. The simulated protein is shown in green, the NCOA1 peptide 936 
cofactor in yellow and dexamethasone ligand shown in light green. At the 0:27 937 
timepoint, the MR:Dexa complex structure is overlaid onto the simulation for 938 
comparison with the protein in light blue and dexamethasone in magenta.  939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
 947 
 948 
 949 
 950 
 951 
 952 
 953 
 954 
 955 
 956 
 957 
 958 
 959 
 960 
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Supplemental experimental procedures 961 
 962 
Protein expression and purification for structure 963 
 964 
GR:Dexa 965 
The cDNA sequence encoding the human GR-LBD (amino acids 500-777) with the 966 
mutations N517D, F602S and C638D and an N-terminal 6-histidine tag followed by a 967 
thrombin cleavage site was cloned into a pFastBac-HTb vector (Life Technologies). 968 
Recombinant baculovirus was generated using the Bac-to-Bac expression system 969 
(Life Technologies) and High Five cells (Life Technologies) were infected followed by 970 
suspension culture in Express Five medium (Gibco) for 48h at 27°C, the last 24h in 971 
the presence of 10 µM dexamethasone, after which cells were collected by 972 
centrifugation. All protein purification steps were performed at 4°C. Cells were lysed 973 
in buffer A (50 mM Tris pH 8.0, 2.5 mM DTT, 1% CHAPS, 50 µM dexamethasone 974 
and 10% glycerol) supplemented with Complete EDTA-free protease inhibitor cocktail 975 
(Roche) followed by affinity purification using Ni-NTA beads (Qiagen). Protein was 976 
eluted in buffer A supplemented with 150 mM NaCl and 300 mM imidazole, and 977 
subjected to size exclusion chromatography using a HiLoad 26/60 Superdex 200 gel 978 
filtration column equilibrated in buffer A. Five-fold molar excess of a TIF2 peptide, 979 
KENALLRYLLDK (Innovagen) was added, the N-terminal 6-histidine tag was 980 
removed using thrombin-agarose (Sigma) and subsequently the free 6-histidine tag 981 
was removed. The protein was thereafter passed over a Q Sepharose fast-flow ion-982 
exchange column (GE Healthcare) equilibrated in buffer A and stored at −80 °C. 983 
Approximately 5.4 mg protein was obtained from 10 L High Five cells. 984 
 985 
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GR:dibC 986 
A pFastBac (Invitrogen) construct encoding human GR-LBD (amino acids 500-777) 987 
with the mutations N517D, V571M, F602S and C638D and an N-terminal, thrombin 988 
cleavable 6-His tag was used to generate baculoviruses in Sf9 cells (Invitrogen). GR-989 
LBD encoding viruses were used to infect High Five cells (Invitrogen) at a density of 990 
2-3x10E6 cells/ml and a MOI of 3 in a Wave Bioreactor at 27oC. 24 hours post-991 
infection, dexamethasone was added to a final concentration of 10 μM. The cells 992 
were harvested by centrifugation 48 hours post-infection, washed in PBS and stored 993 
at -80°C until lysis. Cells were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 994 
10% glycerol, 1% CHAPS, 2.5 mM DTT, Complete EDTA-free protease inhibitor 995 
cocktail (Roche) and 50 μM dexamethasone) and lysed by 5x1 min passes in a 996 
polytron homogeniser. The cell-lysate was clarified by centrifugation at 18500 g for 997 
90 minutes and batch-bound to Ni-NTA Superflow (Qiagen) for 1.5 hours at 4°C. The 998 
IMAC resin was packed in a column, washed with wash buffer (50 mM Tris pH8.0, 60 999 
mM NaCl, 30 mM imidazole, 10% glycerol, 1% CHAPS, 2.5 mM DTT and 50 μM 1000 
dexamethasone) and GR-LBD was step eluted with elution buffer (50 mM Tris pH 1001 
8.0, 30 mM NaCl, 300 mM imidazole, 10% glycerol, 1% CHAPS, 2.5 mM DTT and 50 1002 
μM dexamethasone). The eluate was loaded on a HiLoad 26/60 Superdex 200 size 1003 
exclusion column equilibrated in gel filtration buffer (50 mM Tris-HCl pH 8.0, 10% 1004 
glycerol, 1% CHAPS, 2.5 mM DTT and 50 μM dexamethasone). GR containing 1005 
fractions were pooled and a 3-fold excess of co-activator NR-box peptide 1006 
(KENALLRYLLDK, human NCoA2, residues 740-751) was added. The His-tag was 1007 
cleaved over night at 4o C with Thrombin-agarose (Sigma) and removed by negative 1008 
IMAC using Ni-NTA. The protein was finally polished through Q Sepharose FF (GE 1009 
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Healthcare) equilibrated in gel filtration buffer, flash-frozen in liquid nitrogen and 1010 
stored at -80oC. 1011 
MR:Dexa and MR:dibC 1012 
Human MR-LBD (amino acids 735-984) with the mutations C808S, C910S (and 1013 
S810L in the case of dibC), an N-terminal, TEV cleavable 6-HN tag, and a C-terminal 1014 
thrombin cleavable co-activator peptide PQAQQKSLLQQLLTE was cloned into 1015 
pET24a(+). Escherichia coli BL21 StarTM (DE3) (Invitrogen) cells transfomed with 1016 
the expression vector were grown in terrific broth at 37°C until OD600=0.5-1.0, 1017 
chilled on ice for 30 minutes and 100 μM of dexamethasone (Alfa Aesar) or dibC was 1018 
added. Cells were shaken at 16°C for 30 minutes before protein production was 1019 
induced using 0.1 mM isopropyl β-D-thiogalactopyranoside (IPTG) for an additional 1020 
24-48 hours. Cells were lysed in 30 mM Na-Hepes pH 7.5, 150 mM NaCl, 20 mM 1021 
imidazole, 100 mM arginine-HCl, 10% glycerol, 1% CHAPS and 1 mM TCEP 1022 
containing 20 μM of respective ligand, EDTA-free Complete protease inhibitor 1023 
cocktail (Roche) and 0.05 g/ml of CelLytic™ Express (C1990, SIGMA), by rotation at 1024 
room-temperature for 15 minutes. The lysate was cleared by centrifugation at 48000 1025 
g for 20 minutes and loaded onto Ni-Sepharose FF (GE Healthcare) equilibrated in 1026 
lysis buffer. After washing, protein was step eluted by the addition of one column 1027 
volume (CV) of lysis buffer containing 0.5 M Arginine-HCl followed by 5 CV of elution 1028 
buffer (30 mM Na-Hepes, pH 7.5, 150 mM NaCl, 500 mM imidazole, 500 mM 1029 
arginine-HCl, 10% glycerol, 1% CHAPS, 1 mM TCEP and 20 μM of respective 1030 
ligand). Size exclusion chromatography was performed on a HiLoad Superdex 200 1031 
column (GE Healthcare) equilibrated in 20 mM Na-Hepes pH 6.7, 150 mM NaCl, 0.5 1032 
M arginine-HCl, 10% glycerol, 0.1% CHAPS, 1 mM TCEP and 2 μM dexamethasone 1033 
or dibC. Finally, MR-LBD co-expressed with dexamethasone was diluted 10x in 20 1034 
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mM Tris-HCl pH 8.0, 10 mM CaCl2 and 20 μM dexamethasone, cleaved with TEV 1035 
protease and Thrombin CleanCleave Kit (SIGMA), purified by reverse IMAC on Ni-1036 
Sepharose FF and concentrated to 15 mg/ml. MR-LBD co-expressed with dibC was 1037 
diluted 15x in 10 mM Tris-HCl pH 8.5, 20 μM dibC and 1mM TCEP and concentrated 1038 
to 7 mg/ml. 1039 
Protein expression and purification for biophysical characterization 1040 
GR  1041 
Human GR-LBD (amino acids 529-777) was cloned into the pET24a vector 1042 
(Novagen) featuring an N-terminal His6-tag and a TEV protease cleavage site. The 1043 
expression vector was transformed into E. coli BL21(DE3) STAR, followed by 1044 
expression in PASM-5052 autoinduction medium. 100 μM dexamethasone was 1045 
added after the cell culture reached an OD of 0.6 followed by expression over 48 1046 
hours at 16 °C. All purification buffers were degassed and contained 2 mM TCEP 1047 
and 50 μM dexamethasone. The harvested cells were resuspended in lysis buffer (50 1048 
mM Tris pH 8, 10% glycerol, 1% CHAPS) supplemented by protease inhibitors 1049 
(Complete, Roche) and DNAse. Cells were lysed by sonication. The cleared lysate 1050 
was applied to a nickel affinity column equilibrated with wash buffer (50 mM Tris pH 1051 
8, 10% glycerol, 1% CHAPS, 60 mM NaCl) and eluted by a 300 mM imidazole 1052 
gradient. Remaining impurities were removed by an additional superdex 200 1053 
gelfiltration step using 50 mM Tris buffer at pH 9 as running buffer followed by 1054 
storage at -80°C. 1055 
MR 1056 
Human MR-LBD (amino acids 712-984) with the mutation C808S and an N-terminal, 1057 
TEV cleavable 6-HN tag was cloned and expressed in  the same way as the MR–1058 
LBD proteins used for structure determination. The cells were lysed in 50 mM Tris-1059 
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HCl, pH 8.0, 500 mM NaCl, 100 mM arginine-HCl, 1% CHAPS, 20 mM imidazole, 1060 
10% glycerol, 1mM TCEP, 50 μM dexamethasone, EDTA-free Complete protease 1061 
inhibitor cocktail (Roche) and 0.05 g/ml of CelLytic™ Express (C1990, SIGMA). The 1062 
lysate was cleared by centrifugation at 48000 g for 20 minutes and loaded onto a 1063 
HisTrap HP column (GE Healthcare). The protein was gradient eluted with 50 mM 1064 
Tris-HCl, pH 8.0, 500 mM NaCl, 500 mM arginine-HCl, 1% CHAPS, 0- 300 mM 1065 
imidazole, 10% glycerol, 1mM TCEP, 50 μM dexamethasone. 1066 
Crystallization  1067 
GR:Dexa 1068 
A tube with 1.0 mg of GR(500-777) N517D, F602S and C638D was thawed and 1069 
washed three times in the concentrator tube with 3.5 ml of 10 mM Tris pH 8.5, 2.5 1070 
mM DTT and 45μM dexamethasone. A fivefold molar excess of co-activator NR-box 1071 
peptide (KENALLRYLLDKDD, human NCoA2, residues 740-753) was added and the 1072 
complex was concentrated to 9 mg/ml.  1073 
Crystals were grown at 4°C in hanging drops using 1 μl of protein and 1 μl of well 1074 
solution (10% PEG8000, 10% ethylene glycol and 0.1 M Hepes pH 7.5). Crystals 1075 
were frozen in liquid nitrogen with 20% ethylene glycol as cryo protectant prior to 1076 
data collection.  1077 
GR:dibC 1078 
A tube with 5.0 mg’s of GR(500-777) N517D, V571M, F602S and C638D was thawed 1079 
and concentrated to about 1.5 ml. The protein was washed three times in the 1080 
concentrator tube with 10 ml of 10 mM Tris pH 8.5, and 2.5 mM DTT (buffer B) to 1081 
remove excess of dexamethasone and thereafter diluted to a final volume of 6 ml. 1082 
dibC was added to a final concentration of 0.25 mM to boost ligand exchange prior to 1083 
53 
 
dialysis. Dialysis was performed using two Slide-A-Lyzer dialysis cassettes in a 1084 
beaker containing buffer B and 60 μM of dibC. Dialysis solution was exchanged after 1085 
20, 28 and 46 hours before harvesting the sample. The protein was concentrated to 1 1086 
ml and buffer was exchanged to fresh buffer B using a NAP10 column. A twofold 1087 
molar excess of co-activator NR-box peptide (KENALLRYLLDKDD, human NCoA2, 1088 
residues 740-753) was added and the complex was concentrated to 9 mg/ml.  1089 
Crystals were grown at 4°C in hanging drops using 2 μl of protein and 1 μl of well 1090 
solution (10% PEG8000, 20% ethylene glycol and 0.1 M Hepes pH 7.5). Crystals 1091 
appeared as rod like crystals after 1-2 days but continued to grow for one to two 1092 
weeks. Crystals were frozen in liquid nitrogen without any cryo protectant prior to 1093 
data collection.  1094 
MR:Dexa 1095 
Crystals of MR(735-984) C808S and C910S co-expressed and purified with 1096 
dexamethasone were grown by sitting drop vapor diffusion in 30% PEG4000, 0.1 M 1097 
NaCl and 0.2 M Pipes pH 7.4. Crystals were cryo-protected in well solution 1098 
supplemented with 20% glycerol and flash frozen in liquid nitrogen.  1099 
MR:dibC 1100 
Crystals of MR(735-984) C808S, C910S and S810L co-expressed and purified with 1101 
dibC were grown by sitting drop vapor diffusion in 18% PEG4000, 0.14 M LiSO4, 85 1102 
mM Tris pH 8.5 and 15% glycerol. Crystals were flash frozen in liquid nitrogen.  1103 
 1104 
Data collection and structure determination. 1105 
The MR:Dexa data were collected using an Rigaku FRE rotating anode (wavelength 1106 
1.54 Å). The GR:Dexa data were collected at the ID14:4 beam line at the ESRF 1107 
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(wavelength 0.94 Å). The MR:dibC and GR:dibC data were collected at the ID29 1108 
beam line et the ESRF (wavelength 0.98 Å). All data sets were collected from a 1109 
single crystal at 100K. The MR data sets were integrated with XDS (Kabsch et al., 1110 
2010) and the GR data sets were integrated with Mosflm (Leslie et al., 2007). All data 1111 
sets were merged with SCALA (Evans et al., 2006) from the CCP4 suite 1112 
(Collaborative Computational Project., 1994). The MR and GR structures were solved 1113 
with PHASER (McCoy et al., 2007) using PDB entry 2AA2 and 1M2Z as starting 1114 
models, respectively. The structures were refined using the BUSTER (Bricogne et al., 1115 
2011) and manual rebuilding using Coot (Emsley et al., 2004). The GR:Dexa 1116 
structure had 1 (0.39%) Ramachandran outlier while the other structures did not have 1117 
any outliers. All figures were prepared using PyMOL (www.pymol.org).  1118 
 1119 
Structural analysis 1120 
Cavity volumes were calculated with fpocket 2.0 (Le Guilloux et al. 2009). For a 1121 
higher accuracy, the default number of Monte Carlo steps was increased from 2500 1122 
to 500000. The minimum size of alpha spheres was set to 3.5 Å to avoid connecting 1123 
buried cavities (default value 3.0 Å). 1124 
 1125 
PCA analysis was performed using ProDy 1.5.1 (Bakan et al. 2011) For each 1126 
receptor, all public available structures were included in the analysis and one 1127 
structures was selected as the reference structure (MR:Dexa, GR:Dexa, 1E3G (AR), 1128 
1A28 (PR), 1A52 (ER)). The sequence of monomer A from each protein was aligned 1129 
to the sequence of the reference structure filtering out structures with less than 90% 1130 
sequence identity and subsequently superimposed. The first six principal 1131 
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components were plotted against the residue number by calculating the length of the 1132 
x,y,z-fluctuation vector for each c-alpha atom. 1133 
 1134 
Mineralocorticoid receptor ligand competition binding assay 1135 
Human MR-LBD (729-984)  with an N-terminal maltose binding protein (MBP) tag 1136 
was expressed using the Bac-to-Bac expression system (Life Technologies). High 1137 
Five cells were co-infected with recombinant P23 co-chaperone baculovirus followed 1138 
by suspension culture in Express Five medium (Gibco) for 48h at 27°C. Cells were 1139 
lysed in lysis buffer (10 mM Tris-HCl pH 7.4, 0.5 mM EDTA, 2.5 mM DTT, 10% 1140 
glycerol, 20 mM Na2MoO4 and Complete protease inhibitor (Roche)) followed by 1141 
centrifugation. The supernatant was stored at -80°C. Compound binding was 1142 
assessed using a ligand competition binding scintillation proximity assay (SPA). 1143 
Compounds were incubated with MR-High Five cell lysate (7µg/ml) and 5 nM 3H-1144 
aldosterone (Perkin Elmer NET419250UC) in assay buffer (10 mM Tris-HCl, 0.5 mM 1145 
EDTA, 20 mM Sodium molybdate dehydrate, 10 % Glycerol and 0.1 mM DTT) for 1146 
one hour before addition of 2.5 mg/ml anti-rabbit SPA PS beads (Perkin Elmer 1147 
RPNQ0299) and 2 µg/ml rabbit anti-MBP antibodies (Abcam ab9084) followed by 1148 
incubation at room temperature for 8 hours before detection of signal using a 1149 
LeadSeeker imaging system (GE Healthcare). Ki values where derived using the 1150 
equation Ki = (IC50 - receptor Concentration/2) / (1 + ligand Conc/Km), where 1151 
receptor concentration was set to zero, ligand concentration to 0.005 µM and Km-1152 
value to 0.0016 µM. 1153 
 1154 
 1155 
 1156 
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Biophysical characterization and residence time determination 1157 
Residence time measurements of GR/MR:dexamethasone and dibC was determined 1158 
using single molecule microscopy (SMM) and SPR (Biacore) by probing the time-1159 
reolved change in receptor binding to surface-immobilized co-regulator peptides (GR: 1160 
Biotin-PRGC1_130-155 / MR: PRGC2_146-166). HBSP(+) buffer (10 mM HEPES, 1161 
150 mM NaCl, 0,005% P20, pH=7.4) was used for all measurements. For SPR, the 1162 
two biotinylated peptides was immobilized on a strepavidin chip (GE healthcare) 1163 
using a Biacore 3000 (GE healthcare) to 500-1000 RU. Budesonide/aldosterone was 1164 
added to a final concentration of 25 µM to a solution of 130 nM GR/MR, 1165 
preequilibrated with 1µM dexamethasone/dibC. Directly after budesonide/aldosterone 1166 
addition, receptor binding rate to the cofactor peptide was monitored by consecutive 1167 
injection cycles (1 min injections). The peptide surface was regenerated with 0.005% 1168 
SDS after each injection. To compensate for potential protein degradation over the 1169 
time course of the measurement, the data was normalized to a reference sample 1170 
containing only 1uM dexamethasone/dibC. For SMM, the respective NHR was bound 1171 
via 6×His-tag to liposomes containing POPC, DGS-NTA, lissamine rhodamine B 1172 
sulfonyl in a ratio of 1:0.02:0.01. Liposomes were prepared as described by 1173 
Gunnarsson Anal chem. 2015. The coregulator peptides were mixed with Neutravidin 1174 
(NA) in a 1:1 molar ratio. Subsequently, the coregulator peptide-NA complex was 1175 
incubated at 50 µg/ml NA with TL1 cleaned PLL-g-PEG/ PLL-g-PEG-biotin (1:1, 1176 
Surface Solutions) coated glass surfaces. Budesonide/aldosterone was added to a 1177 
final concentration of 10 µM to a 150 pM liposome-NHR solution containing 1 µM 1178 
dexamethasone/dibC. To compensate for potential protein degradation over time the 1179 
data was normalized to a reference sample of 150 pM liposome-NHR solution 1180 
containing only 1uM dexamethasone/dibC. Image data was collected on an inverted 1181 
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microscope (Nikon Ti Eclipse) equipped with a 60x oil immersion objective (NA = 1182 
1.49), TRITC filter cube, perfect focus system and air cooled sCMOS (Orca Flash 4.0 1183 
v2 Hamamatsu). For imaging in an iterative fashion, 10 sec time series at 10Hz 1184 
framerate were recorded for the competition and the reference well at two different 1185 
positions continuously over ~15 minutes. Images were analyzed using custom made 1186 
Matlab (Mathworks) routines to extract the liposome-NHR conjugate binding rate to 1187 
the surface. The liposome-NHR binding rate during each time series (10 sec) was 1188 
assumed to be constant and hence, the vesicle binding rate was extracted by linear 1189 
regression to the cumulative number of binding liposomes as a function of time. To 1190 
compensate for surface preparation inhomogeneities the data of the two different 1191 
positions in each well were averaged. The extracted binding rates were plotted over 1192 
time and fitted with 𝑘𝑘+(𝑡𝑡) = 𝑎𝑎𝑒𝑒−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡 + 𝑐𝑐. 1193 
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